세계의 단일염기다형성(SNP) 지노타이핑 시장 보고서(2025년)
Single Nucleotide Polymorphism (SNP) Genotyping Global Market Report 2025
상품코드 : 1824457
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

단일염기다형성(SNP) 지노타이핑 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 19.2%로 성장할 전망이며, 248억 9,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 질병 연구에 있어서 용도의 확대, 정밀 의료에 대한 수요 증가, 바이오 뱅크 구상 확대, 유전자 검사 급증, 작물 개량을 위한 농업에서의 채용 증가에 기인하고 있습니다. 예측 기간 주요 동향으로는 차세대 시퀀싱(NGS)의 이용 확대, 약리 유전체학에서의 SNP 지노타이핑 수요 증가, 소비자 직접 유전자 검사의 출현, 자동화에 대한 주력, 고스루풋 지노타이핑 플랫폼 등이 있습니다.

향후 5년간의 성장률 19.2%라고 하는 예측은 전회 예측으로부터 0.2%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 무역 마찰은 한국과 독일에서 개발된 마이크로어레이 칩과 TaqMan 분석의 가격을 상승시켜 파마코유전체학 검사의 지연 및 분자 진단 비용의 상승을 초래함으로써 미국에서 대규모 단일염기다형성(SNP) 지노타이핑의 채용을 방해할 수 있습니다. 또한 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

만성 질환의 유병률 증가는 향후 수년간 단일염기다형성(SNP) 지노타이핑 시장의 성장을 이끌 것으로 예측됩니다. 만성 질환은 1년 이상 지속되는 건강 문제이며, 지속적인 의료가 필요하며 일상 생활을 제한하는 경우가 많습니다. SNP 유전형은 유전적 소인을 확인하고 만성 질환의 만연에 대응하는 개인화된 의료를 진행하는 데 중요한 역할을 합니다. 예를 들어 2024년 6월 호주 정부 기관인 호주 보건복지연구소는 만성질환과 관련된 사망률이 2021년 인구 10만 명당 459명에서 2022년에는 인구 10만 명당 490명으로 증가했다고 보고했습니다. 그 결과, 만성질환의 부담 증가가 단일염기다형성(SNP) 지노타이핑 시스템 시장의 성장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Single nucleotide polymorphism (SNP) genotyping is a procedure that identifies and describes genetic variants at the level of specific DNA nucleotides. It focuses on pinpointing individual SNPs, which are single-base changes in DNA sequences. This process is crucial for gaining insights into genetic variations associated with diseases, traits, and population studies.

The primary products of single nucleotide polymorphism (SNP) genotyping include consumables, instruments, and services. Consumables refer to items that people and businesses regularly consume or use up, requiring replacement, such as food and home supplies. Various technologies are employed in SNP genotyping, including TaqMan SNP genotyping, Mass Array SNP genotyping, SNP gene chip arrays, and others. These technologies find applications in diverse fields such as animal genetics, plant improvement, diagnostic research, pharmaceuticals and pharmacogenomics, agricultural biotechnology, and more.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The single nucleotide polymorphism (SNP) genotyping market research report is one of a series of new reports from The Business Research Company that provides single nucleotide polymorphism (SNP) genotyping market statistics, including the single nucleotide polymorphism (SNP) genotyping industry's global market size, regional shares, competitors with a single nucleotide polymorphism (SNP) genotyping market share, detailed single nucleotide polymorphism (SNP) genotyping market segments, market trends and opportunities, and any further data you may need to thrive in the single nucleotide polymorphism (SNP) genotyping industry. This single nucleotide polymorphism (SNP) genotyping market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The single nucleotide polymorphism (snp) genotyping market size has grown rapidly in recent years. It will grow from $10.3 billion in 2024 to $12.34 billion in 2025 at a compound annual growth rate (CAGR) of 19.8%. The growth in the historic period can be attributed to increasing research in genomics, rise in genetic disorders, growth in personalized medicine, expanding pharmaceutical industry, and rising demand for molecular diagnostics.

The single nucleotide polymorphism (snp) genotyping market size is expected to see rapid growth in the next few years. It will grow to $24.89 billion in 2029 at a compound annual growth rate (CAGR) of 19.2%. The growth in the forecast period can be attributed to growing applications in disease research, a rise in demand for precision medicine, expanding biobanking initiatives, the surge in genetic testing, and rising adoption in agriculture for crop improvement. Major trends in the forecast period include increasing use of next-generation sequencing (NGS), rising demand for SNP genotyping in pharmacogenomics, the emergence of direct-to-consumer genetic testing, focus on automation, and high-throughput genotyping platforms.

The forecast of 19.2% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of large-scale Single Nucleotide Polymorphism genotyping by inflating prices of microarray chips and TaqMan assays developed in South Korea and Germany, resulting in slower pharmacogenomic testing and higher molecular diagnostics costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of chronic conditions is anticipated to drive the growth of the single nucleotide polymorphism (SNP) genotyping market in the coming years. Chronic conditions are health issues that persist for a year or longer, requiring ongoing medical care and often limiting daily activities. SNP genotyping plays a crucial role in identifying genetic predispositions and advancing personalized medicine in response to the growing prevalence of chronic diseases. For example, in June 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that the death rate associated with chronic conditions increased from 459 deaths per 100,000 people in 2021 to 490 deaths per 100,000 people in 2022. Consequently, the increasing burden of chronic conditions is driving the growth of the single nucleotide polymorphism (SNP) genotyping systems market.

The increasing funding for genomic research is expected to drive the growth of the single nucleotide polymorphism (SNP) genotyping market in the future. Funding for genomic research refers to the financial resources allocated, granted, or invested to support activities in the field of genomics. Such funding is crucial for advancing SNP studies by facilitating various research initiatives, technology development, and collaborative projects. For instance, in September 2024, the National Institutes of Health (NIH), a US-based government agency, announced the allocation of $27 million to establish a new network of genomics-enabled learning health systems. Therefore, the rise in funding for genomic research is propelling the growth of the single nucleotide polymorphism (SNP) genotyping market.

A prominent trend in the single nucleotide polymorphism (SNP) genotyping market is the adoption of technological solutions. Major companies in this market are introducing advanced solutions to maintain their market position. For instance, in May 2022, Neogen Corporation and Gencove launched InfiniSEEK, the first complete genome and genotyping tool for cattle breeders. InfiniSEEK's validation demonstrates high concordance with deep whole-genome sequencing, providing clinical-grade accuracy in specific areas of interest. This technological advancement underscores the commitment of companies to bring innovative solutions to the single nucleotide polymorphism (SNP) genotyping market.

Companies in the single nucleotide polymorphism (SNP) genotyping market are also focusing on developing biomarkers for coronary heart disease detection, enhancing market profitability. Single nucleotide polymorphism (SNP) biomarkers associated with coronary heart disease (CHD) detection are genetic variations linked to an increased risk of CHD. For instance, Cardio Diagnostics launched PrecisionCHD in February 2023, an AI-driven blood test utilizing epigenetic and genetic biomarkers to detect CHD. This non-invasive test eliminates the need for traditional methods, providing objectivity through biomarkers rather than self-reported patient data.

In December 2023, Neogen Corporation, a US-based food safety company known for its diverse genomic technologies, particularly in single nucleotide polymorphism (SNP) genotyping, formed a partnership with TerraNova Equestrian Center. This collaboration aims to strengthen biosecurity measures at TerraNova Equestrian Center by implementing Neogen's advanced cleaning and disinfectant solutions. The focus is on protecting the health of horses and their owners while fostering a safe environment for equestrian competitions. TerraNova Equestrian Center is a US-based facility that offers premier services for riders and horses.

Major companies operating in the single nucleotide polymorphism (SNP) genotyping market include Thermo Fischer Scientific Inc., Danaher Corporation, Roche Diagnostics Corporation, GE HealthCare Technologies Inc., Eurofins Genomics LLC, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Sigma-Aldrich Corporation, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Promega Corporation, GenScript Biotech Corporation, Integrated DNA Technologies Inc., LGC Ltd., Sequenom Inc., Fluidigm Corporation, Agendia Inc., Nugen Technologies Inc., BioChain Institute Inc., Standard BioTools Inc., Oxford Gene Technology, Affymetrix Inc., PREMIER Biosoft International Inc., GenoLogics, Rubicon Genomics Inc., Xcelris Genomics, Douglas Scientific LLC, Golden Helix Inc.

North America was the largest region in the single nucleotide polymorphism (SNP) genotyping market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single nucleotide polymorphism (snp) genotyping market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the single nucleotide polymorphism (snp) genotyping market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The single nucleotide polymorphism (SNP) genotyping market includes revenues earned by providing sample collection, DNA extraction, high-resolution melting analysis, and related next-generation sequencing. The market value includes the value of related goods sold by the service provider or included within the service offering. The single nucleotide polymorphism (SNP) genotyping market consists of sales of mass spectrometry-based SNP genotyping and allele-specific PCR. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Single Nucleotide Polymorphism (SNP) Genotyping Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on single nucleotide polymorphism (snp) genotyping market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for single nucleotide polymorphism (snp) genotyping ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The single nucleotide polymorphism (snp) genotyping market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Single Nucleotide Polymorphism (SNP) Genotyping Market Characteristics

3. Single Nucleotide Polymorphism (SNP) Genotyping Market Trends And Strategies

4. Single Nucleotide Polymorphism (SNP) Genotyping Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Single Nucleotide Polymorphism (SNP) Genotyping Growth Analysis And Strategic Analysis Framework

6. Single Nucleotide Polymorphism (SNP) Genotyping Market Segmentation

7. Single Nucleotide Polymorphism (SNP) Genotyping Market Regional And Country Analysis

8. Asia-Pacific Single Nucleotide Polymorphism (SNP) Genotyping Market

9. China Single Nucleotide Polymorphism (SNP) Genotyping Market

10. India Single Nucleotide Polymorphism (SNP) Genotyping Market

11. Japan Single Nucleotide Polymorphism (SNP) Genotyping Market

12. Australia Single Nucleotide Polymorphism (SNP) Genotyping Market

13. Indonesia Single Nucleotide Polymorphism (SNP) Genotyping Market

14. South Korea Single Nucleotide Polymorphism (SNP) Genotyping Market

15. Western Europe Single Nucleotide Polymorphism (SNP) Genotyping Market

16. UK Single Nucleotide Polymorphism (SNP) Genotyping Market

17. Germany Single Nucleotide Polymorphism (SNP) Genotyping Market

18. France Single Nucleotide Polymorphism (SNP) Genotyping Market

19. Italy Single Nucleotide Polymorphism (SNP) Genotyping Market

20. Spain Single Nucleotide Polymorphism (SNP) Genotyping Market

21. Eastern Europe Single Nucleotide Polymorphism (SNP) Genotyping Market

22. Russia Single Nucleotide Polymorphism (SNP) Genotyping Market

23. North America Single Nucleotide Polymorphism (SNP) Genotyping Market

24. USA Single Nucleotide Polymorphism (SNP) Genotyping Market

25. Canada Single Nucleotide Polymorphism (SNP) Genotyping Market

26. South America Single Nucleotide Polymorphism (SNP) Genotyping Market

27. Brazil Single Nucleotide Polymorphism (SNP) Genotyping Market

28. Middle East Single Nucleotide Polymorphism (SNP) Genotyping Market

29. Africa Single Nucleotide Polymorphism (SNP) Genotyping Market

30. Single Nucleotide Polymorphism (SNP) Genotyping Market Competitive Landscape And Company Profiles

31. Single Nucleotide Polymorphism (SNP) Genotyping Market Other Major And Innovative Companies

32. Global Single Nucleotide Polymorphism (SNP) Genotyping Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Single Nucleotide Polymorphism (SNP) Genotyping Market

34. Recent Developments In The Single Nucleotide Polymorphism (SNP) Genotyping Market

35. Single Nucleotide Polymorphism (SNP) Genotyping Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기